Market Summary
USD110.76-1.70
Market Closed-1.51%
ZBH Stock Price
ZBH RSI Chart
ZBH Valuation
ZBH Price/Sales (Trailing)
ZBH Profitability
ZBH Fundamentals
ZBH Revenue
ZBH Earnings
Price Action
52 Week Range
102.60149.25
(Low)(High)
Last 7 days
-7.9%
Last 30 days
-5.8%
Last 90 days
-23.7%
Trailing 12 Months
5.9%
ZBH Financial Health
ZBH Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ZBH
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-30 | Kolli Sreelakshmi | bought | 120,370 | 120 | 1,000 | - |
2023-08-28 | HAGEMANN ROBERT | bought | 232,960 | 116 | 2,000 | - |
2023-08-25 | BERNARD BETSY J | bought | 100,023 | 114 | 871 | - |
2023-08-25 | MICHELSON MICHAEL W | bought | 150,150 | 115 | 1,300 | - |
2023-08-23 | HIGGINS ARTHUR J | bought | 115,613 | 115 | 1,000 | - |
2023-07-01 | VAN ZUILEN WILFRED | acquired | - | - | 2,633 | pres, europe, m. east & africa |
2023-07-01 | Upadhyay Suketu | sold (taxes) | -245,697 | 146 | -1,677 | exec. vp, cfo |
2023-07-01 | Upadhyay Suketu | acquired | - | - | 3,768 | exec. vp, cfo |
2023-06-01 | Stellato Paul A | sold (taxes) | -25,056 | 127 | -197 | vp, controller & cao |
2023-06-01 | Stellato Paul A | acquired | - | - | 628 | vp, controller & cao |
Which funds bought or sold ZBH recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | sold off | -100 | -11,057,600 | - | -% |
2023-09-21 | Jefferies Group LLC | new | - | 810,263 | 810,263 | 0.01% |
2023-09-21 | Baystate Wealth Management LLC | unchanged | - | 1,789 | 15,666 | -% |
2023-09-20 | BARCLAYS PLC | added | 89.02 | 36,139,000 | 68,115,000 | 0.04% |
2023-09-12 | DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | sold off | -100 | -1,938,000 | - | -% |
2023-09-12 | Farther Finance Advisors, LLC | added | 67.14 | 23,974 | 51,106 | 0.01% |
2023-09-07 | ST GERMAIN D J CO INC | new | - | 10,634,300 | 10,634,300 | 0.56% |
2023-08-28 | DT Investment Partners, LLC | unchanged | - | -4,002 | 80,685 | 0.01% |
2023-08-25 | EUBEL BRADY & SUTTMAN ASSET MANAGEMENT INC | added | 0.58 | 3,068,000 | 26,046,000 | 3.59% |
2023-08-24 | Alberta Investment Management Corp | reduced | -79.96 | -19,202,800 | 5,600,650 | 0.05% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Zimmer Biomet Holdings
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | price t rowe associates inc /md/ | 5.3% | 11,200,109 | SC 13G | |
| Feb 09, 2023 | vanguard group inc | 11.46% | 24,055,739 | SC 13G/A | |
| Jan 30, 2023 | blackrock inc. | 10.4% | 21,803,709 | SC 13G/A | |
| Jan 24, 2023 | blackrock inc. | 10.4% | 21,803,709 | SC 13G/A | |
| Apr 08, 2022 | vanguard group inc | 11.04% | 23,102,761 | SC 13G/A | |
| Jan 28, 2022 | jpmorgan chase & co | 5.4% | 11,340,168 | SC 13G | |
| Jan 28, 2022 | blackrock inc. | 10.4% | 21,793,439 | SC 13G/A | |
| Apr 12, 2021 | blackrock inc. | 10.0% | 20,926,542 | SC 13G/A | |
| Feb 11, 2021 | massachusetts financial services co /ma/ | 4.8% | 10,001,947 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 7.58% | 15,703,785 | SC 13G/A |
Recent SEC filings of Zimmer Biomet Holdings
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 4 | Insider Trading | |
| Aug 29, 2023 | 4 | Insider Trading | |
| Aug 29, 2023 | 4 | Insider Trading | |
| Aug 25, 2023 | 4 | Insider Trading | |
| Aug 22, 2023 | 8-K | Current Report | |
| Aug 01, 2023 | 10-Q | Quarterly Report | |
| Aug 01, 2023 | 8-K | Current Report |
Peers (Alternatives to Zimmer Biomet Holdings)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
MDT | 104.1B | 31.6B | -3.89% | -3.30% | 28.69 | 3.3 | 1.57% | -30.40% |
ISRG | 102.4B | 6.7B | -3.33% | 56.36% | 71.85 | 15.36 | 11.75% | -0.66% |
SYK | 101.2B | 19.5B | -4.23% | 31.95% | 37.36 | 5.2 | 10.36% | 30.30% |
BDX | 71.3B | 19.0B | -8.08% | 14.20% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 42.6B | 5.7B | -7.79% | -14.88% | 30.67 | 7.53 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 9.2B | 937.8M | -4.69% | 30.64% | 316.65 | 9.84 | 16.30% | 250.21% |
SWAV | 7.3B | 616.6M | -6.84% | -23.46% | 30.01 | 11.87 | 69.52% | 343.68% |
GMED | 5.0B | 1.1B | -7.21% | -13.95% | 23.85 | 4.57 | 12.63% | 50.85% |
IRTC | 2.8B | 452.1M | -9.56% | -23.21% | -28.09 | 6.17 | 24.99% | 24.09% |
TNDM | 1.4B | 790.3M | -20.84% | -55.28% | -6.03 | 1.71 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
AVNS | 955.9M | 780.7M | -5.94% | -5.33% | -26.55 | 1.22 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
BLFS | 610.4M | 162.2M | 26.12% | -37.36% | -7.26 | 3.76 | 9.71% | 12.37% |
SILK | 590.7M | 162.9M | -24.99% | -65.29% | -11.17 | 3.63 | 42.67% | 12.82% |
Zimmer Biomet Holdings News
Returns for ZBH
Cumulative Returns on ZBH
4%
10-Year Cumulative Returns
-1.1%
7-Year Cumulative Returns
-2.3%
5-Year Cumulative Returns
-5.2%
3-Year Cumulative Returns
Risks for ZBH
What is the probability of a big loss on ZBH?
70.4%
Probability that Zimmer Biomet Holdings stock will be more than 20% underwater in next one year
34.6%
Probability that Zimmer Biomet Holdings stock will be more than 30% underwater in next one year.
18.5%
Probability that Zimmer Biomet Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ZBH drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Zimmer Biomet Holdings was unfortunately bought at previous high price.
Drawdowns
Financials for Zimmer Biomet Holdings
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 1.2% | 7,196 | 7,108 | 6,940 | 6,892 | 6,908 | 6,889 | 6,827 | 7,135 | 7,379 | 6,842 | 7,025 | 7,065 | 7,028 | 7,791 | 7,982 | 7,928 | 7,872 | 7,891 | 7,933 | 7,930 | 7,907 |
| S&GA Expenses | 1.1% | 2,824 | 2,793 | 2,762 | 2,840 | 2,869 | 2,871 | 2,843 | 2,467 | 2,573 | 2,541 | 2,713 | 2,632 | 2,669 | 2,843 | 2,810 | 3,460 | 3,422 | 3,374 | 3,379 | 3,246 | 3,170 |
| EBITDA | -100.0% | - | 1,342 | 1,165 | 1,155 | 1,050 | 1,167 | 1,277 | 1,599 | 1,685 | 1,285 | 546 | 629 | 548 | 902 | 1,685 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.19* | 0.17* | 0.17* | 0.15* | 0.15* | 0.16* | 0.21* | 0.22* | 0.18* | 0.08* | 0.09* | 0.08* | 0.12* | 0.21* | - | - | - | - | - | - |
| Interest Expenses | -7.4% | -184 | -171 | -164 | -171 | -181 | -197 | -208 | -212 | -214 | -213 | -212 | -211 | -214 | -219 | -227 | -243 | -253 | -269 | -289 | -793 | -643 |
| Earnings Before Taxes | 13.1% | 666 | 589 | 404 | 394 | 408 | 386 | 499 | 948 | 1,013 | 613 | -105 | -206 | -277 | 85.00 | 880 | -249 | -280 | -202 | -271 | 471 | 444 |
| EBT Margin | -100.0% | - | 0.08* | 0.06* | 0.06* | 0.04* | 0.04* | 0.05* | 0.10* | 0.11* | 0.06* | -0.04* | -0.03* | -0.04* | 0.01* | 0.11* | - | - | - | - | - | - |
| Net Income | 12.4% | 506 | 450 | 231 | 278 | 230 | 218 | 402 | 819 | 916 | 568 | -138 | -151 | 37.00 | 377 | 1,132 | -90.20 | -359 | -307 | -379 | 1,753 | 1,690 |
| Net Income Margin | -100.0% | - | 0.06* | 0.03* | 0.04* | 0.03* | 0.03* | 0.05* | 0.11* | 0.12* | 0.08* | -0.02* | -0.02* | 0.01* | 0.05* | 0.14* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 1,150 | 1,168 | 1,276 | 1,294 | 1,416 | 1,356 | 1,428 | 1,399 | 895 | 1,087 | 1,061 | 1,230 | 1,544 | 1,379 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 0.2% | 21,294 | 21,244 | 21,066 | 21,333 | 21,453 | 21,618 | 23,456 | 24,009 | 24,223 | 24,027 | 24,418 | 24,026 | 23,648 | 25,513 | 24,639 | 24,315 | 24,206 | 24,289 | 24,127 | 25,382 | 25,491 |
| Current Assets | -0.5% | 4,388 | 4,412 | 4,427 | 4,534 | 4,463 | 4,517 | 4,885 | 5,312 | 5,357 | 5,000 | 5,083 | 5,153 | 4,707 | 6,371 | 4,724 | 4,402 | 4,391 | 4,499 | 4,427 | 4,513 | 4,475 |
| Cash Equivalents | -3.1% | 320 | 330 | 376 | 545 | 386 | 436 | 378 | 920 | 1,042 | 724 | 775 | 967 | 713 | 2,434 | 618 | 513 | 403 | 587 | 543 | 525 | 481 |
| Inventory | 1.5% | 2,276 | 2,241 | 2,147 | 2,129 | 2,123 | 2,132 | 2,148 | 2,517 | 2,533 | 2,512 | 2,174 | 2,492 | 2,497 | 2,463 | 2,385 | 2,362 | 2,345 | 2,310 | 2,257 | 2,220 | 2,159 |
| Net PPE | 3.6% | 1,975 | 1,906 | 1,873 | 1,802 | 1,797 | 1,826 | 1,837 | 2,008 | 2,005 | 2,022 | 1,864 | 2,043 | 2,057 | 2,066 | 2,077 | 2,055 | 2,036 | 2,014 | 2,015 | 2,002 | 1,987 |
| Goodwill | 0.1% | 8,744 | 8,735 | 8,580 | 8,799 | 8,869 | 8,896 | 8,919 | 9,212 | 9,248 | 9,233 | 8,983 | 9,039 | 8,982 | 8,951 | 9,197 | 9,545 | 9,594 | 9,570 | 9,594 | 10,584 | 10,596 |
| Liabilities | -1.9% | 8,916 | 9,086 | 9,039 | 9,082 | 9,328 | 9,596 | 10,790 | 11,294 | 11,640 | 11,577 | 12,218 | 12,147 | 12,004 | 13,630 | 12,246 | 12,230 | 12,544 | 12,750 | 12,851 | 13,159 | 13,447 |
| Current Liabilities | -4.4% | 2,234 | 2,336 | 2,358 | 2,296 | 2,464 | 2,674 | 3,468 | 2,939 | 2,929 | 2,089 | 2,557 | 2,266 | 2,161 | 3,780 | 3,442 | 3,774 | 3,678 | 2,255 | 2,421 | 2,391 | 1,854 |
| LT Debt, Current | -11.1% | 520 | 585 | 544 | 659 | 852 | 1,015 | 1,605 | 1,046 | 1,050 | 300 | 500 | 450 | 450 | 1,950 | 1,500 | 2,000 | 2,000 | 500 | 525 | 600 | 100 |
| LT Debt, Non Current | -0.3% | 5,189 | 5,205 | 5,152 | 5,055 | 5,172 | 5,286 | 5,464 | 6,458 | 6,803 | 7,539 | 7,627 | 7,840 | 7,759 | 7,724 | 6,721 | 6,346 | 6,719 | 8,311 | 8,414 | 8,597 | 9,413 |
| Shareholder's Equity | 1.8% | 12,372 | 12,158 | 12,020 | 12,245 | 12,125 | 12,021 | 12,666 | 12,714 | 12,583 | 12,450 | 12,199 | 11,878 | 11,644 | 11,883 | 12,393 | 12,086 | 11,662 | 11,539 | 11,276 | 12,223 | 12,044 |
| Retained Earnings | 1.6% | 9,902 | 9,742 | 9,559 | 9,740 | 9,607 | 9,503 | 10,292 | 10,426 | 10,331 | 10,238 | 10,087 | 9,803 | 9,610 | 9,866 | 10,427 | 10,155 | 9,773 | 9,688 | 9,491 | 10,441 | 10,328 |
| Additional Paid-In Capital | 0.8% | 9,766 | 9,692 | 9,504 | 9,464 | 9,419 | 9,386 | 9,315 | 9,295 | 9,249 | 9,199 | 9,122 | 9,073 | 9,014 | 8,984 | 8,920 | 8,867 | 8,777 | 8,748 | 8,686 | 8,662 | 8,597 |
| Shares Outstanding | -0.4% | 209 | 209 | - | 210 | 210 | 209 | - | 209 | 209 | 208 | - | 212 | 212 | 212 | - | 211 | 210 | 210 | - | 209 | 208 |
| Minority Interest | 2.9% | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | 6.00 | 3.00 | 4.00 | 5.00 | 4.00 | 3.00 | 5.00 | 5.00 | 6.00 | 1.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 0.2% | 1,351 | 1,348 | 1,356 | 1,450 | 1,423 | 1,497 | 1,404 | 1,363 | 1,320 | 848 | 1,076 | 1,007 | 1,203 | 1,557 | 1,390 | 1,542 | 1,448 | 1,541 | 1,747 | 1,771 | 1,750 |
| Share Based Compensation | 5.9% | 113 | 107 | 105 | 93.00 | 84.00 | 79.00 | 76.00 | 73.00 | 78.00 | 77.00 | 74.00 | 78.00 | 76.00 | 73.00 | 77.00 | 82.00 | 80.00 | 72.00 | 66.00 | 59.00 | 52.00 |
| Cashflow From Investing | 0.0% | -590 | -590 | -522 | -533 | -560 | -416 | -443 | -585 | -564 | -551 | -564 | -351 | -423 | -660 | -644 | -673 | -649 | -420 | -416 | -462 | -444 |
| Cashflow From Financing | 4.3% | -823 | -860 | -775 | -1,118 | -1,350 | -1,232 | -1,306 | -934 | -551 | -2,108 | -420 | -315 | -571 | 850 | -777 | -872 | -872 | -2,279 | -1,302 | -1,259 | -1,282 |
| Dividend Payments | 0% | 201 | 201 | 201 | 201 | 201 | 201 | 200 | 200 | 199 | 199 | 199 | 198 | 198 | 197 | 197 | 196 | 196 | 196 | 195 | 195 | 195 |
| Buy Backs | -47.3% | 564 | 1,070 | 126 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ZBH Income Statement
2023-06-30Condensed Consolidated Statements of Earnings (unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Net Sales | $ 1,869.6 | $ 1,781.8 | $ 3,700.6 | $ 3,445.0 |
| Type of Revenue [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
| Cost of products sold, excluding intangible asset amortization | $ 525.5 | $ 511.0 | $ 1,026.3 | $ 1,011.0 |
| Type of Cost, Good or Service [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
| Intangible asset amortization | $ 138.2 | $ 133.0 | $ 271.6 | $ 263.8 |
| Research and development | 118.1 | 99.4 | 228.5 | 196.3 |
| Selling, general and administrative | 725.8 | 695.2 | 1,441.8 | 1,379.7 |
| Intangible asset impairment | 3.0 | 3.0 | ||
| Restructuring and other cost reduction initiatives | 24.4 | 57.0 | 66.3 | 100.9 |
| Quality remediation | 7.8 | 14.3 | ||
| Acquisition, integration, divestiture and related | 7.9 | (5.5) | 9.1 | (3.3) |
| Operating expenses | 1,539.9 | 1,500.9 | 3,043.6 | 2,965.7 |
| Operating Profit | 329.6 | 280.9 | 656.9 | 479.3 |
| Other (expense) income, net | (1.2) | (42.6) | 6.5 | (98.7) |
| Interest expense, net | (51.6) | (38.8) | (99.8) | (79.9) |
| Earnings from continuing operations before income taxes | 276.8 | 199.5 | 563.6 | 300.7 |
| Provision for income taxes from continuing operations | 66.9 | 45.5 | 121.0 | 73.5 |
| Net Earnings from continuing operations | 209.9 | 154.0 | 442.6 | 227.2 |
| Less: Net earnings attributable to noncontrolling interest | 0.2 | 0.3 | 0.5 | 0.5 |
| Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc. | 209.6 | 153.7 | 442.1 | 226.7 |
| Loss from discontinued operations, net of taxes | (58.8) | |||
| Net Earnings of Zimmer Biomet Holdings, Inc. | $ 209.6 | $ 153.7 | $ 442.1 | $ 167.9 |
| Earnings Per Common Share - Basic | ||||
| Earnings from continuing operations | $ 1.00 | $ 0.73 | $ 2.12 | $ 1.08 |
| Loss from discontinued operations | (0.28) | |||
| Net Earnings Per Common Share - Basic | 1.00 | 0.73 | 2.12 | 0.80 |
| Earnings Per Common Share - Diluted | ||||
| Earnings from continuing operations | 1.00 | 0.73 | 2.10 | 1.08 |
| Loss from discontinued operations | (0.28) | |||
| Net Earnings Per Common Share - Diluted | $ 1.00 | $ 0.73 | $ 2.10 | $ 0.80 |
| Weighted Average Common Shares Outstanding | ||||
| Basic | 208.6 | 209.6 | 209.0 | 209.4 |
| Diluted | 209.9 | 210.3 | 210.1 | 210.2 |
ZBH Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current Assets: | ||
| Cash and cash equivalents | $ 319.8 | $ 375.7 |
| Accounts receivable, less allowance for credit losses | 1,367.3 | 1,381.5 |
| Inventories | 2,275.8 | 2,147.2 |
| Prepaid expenses and other current assets | 425.1 | 522.9 |
| Total Current Assets | 4,387.9 | 4,427.3 |
| Property, plant and equipment, net | 1,975.0 | 1,872.5 |
| Goodwill | 8,743.7 | 8,580.2 |
| Intangible assets, net | 5,027.7 | 5,063.8 |
| Other assets | 1,160.0 | 1,122.2 |
| Total Assets | 21,294.3 | 21,066.0 |
| Current Liabilities: | ||
| Accounts payable | 354.6 | 354.1 |
| Income taxes payable | 81.6 | 38.5 |
| Other current liabilities | 1,277.6 | 1,421.3 |
| Current portion of long-term debt | 520.0 | 544.3 |
| Total Current Liabilities | 2,233.7 | 2,358.2 |
| Deferred income taxes, net | 474.9 | 474.8 |
| Long-term income tax payable | 375.7 | 421.2 |
| Other long-term liabilities | 642.0 | 632.6 |
| Long-term debt | 5,189.4 | 5,152.2 |
| Total Liabilities | 8,915.8 | 9,039.0 |
| Commitments and Contingencies (Note 16) | ||
| Stockholders' Equity: | ||
| Common stock, $0.01 par value, one billion shares authorized, 315.8 million shares as of June 30, 2023 (313.8 million as of December 31, 2022) issued | 3.2 | 3.1 |
| Paid-in capital | 9,766.0 | 9,504.4 |
| Retained earnings | 9,902.3 | 9,559.3 |
| Accumulated other comprehensive loss | (177.8) | (179.3) |
| Treasury stock, 107.0 million shares as of June 30, 2023 (104.8 million as of December 31, 2022) | (7,122.2) | (6,867.2) |
| Total Zimmer Biomet Holdings, Inc. stockholders' equity | 12,371.5 | 12,020.3 |
| Noncontrolling interest | 7.1 | 6.7 |
| Total Stockholders' Equity | 12,378.6 | 12,027.0 |
| Total Liabilities and Stockholders' Equity | $ 21,294.3 | $ 21,066.0 |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.